You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Electrical System for Rapid Bacterial Cultures

    SBC: TECHSHOT, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad, long-term objective of the proposed project Electrical System for Rapid Bacterial Cultures is to develop an automated electrical impedance analyzer for measuring bacterial growth in contaminated blood. Thepurpose of the System is to hasten the time to diagnose sepsis from 1-2 days down to a few hours. The specific aims of the project are to (1) bui ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Metallo-beta-lactamase Inhibitors

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as NDM-1 are found on mobile genetic elements which are rapidly spreading in Enterobacteriaceae and threaten to erode the future utility of the - lactam antibiotics (i.e. penicillins, cephalosporins, c ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Preserving beta-lactam utility against pathogens producing all classes of beta-la

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR Grant focuses on advancement of a new class of inhibitors of serine-based b-lactamases (Ambler classes A, C and D), for combination with the only subclass of b-lactams (the monobactams) that are not sensitive to zinc-based enzymes (Ambler Class B). Full coverage against all classes of b-lactamases is critically important in light of the alarmi ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid Response Vaccines for Botulinum Neurotoxins

    SBC: Iterative Therapeutics Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum neurotoxins (BoNTs) are the most potent protein toxins known. Given their potent toxicity and their potential use in bio-warfare scenarios, BoNTs are included among the Category A select agents. The currentlyavailable pentavalent toxoid vaccine requires multiple boosters before being effective, and protects unequally against the different BoNT serotyp ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. High-throughput Epitope Mapping of Anti-Viral Antibodies

    SBC: INTEGRAL MOLECULAR INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The identification of highly potent and broadly neutralizing antibodies isolated from HIV-1- infected donors suggests that when presented with a suitable antigenic structure, the human immune system can produce protective antibodies that HIV-1 is unable to evade. Understanding these antigenic structures is a primary objective in developing a vaccine capable of ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Contrast agents for high-sensitivity ultrasound molecular imaging of tumor angiog

    SBC: TARGESON, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Molecular imaging techniques have strong potential in the setting of preclinical research, primarily for drug discovery and basic science in the field of cancer research. In particular, high-frequency ultrasound is a powerful imaging modality for phenotyping and monitoring the response to experimental therapy. Relative to other molecular imaging techniques, ult ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Riluzole Prodrugs for Melanoma and ALS

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Metastatic melanoma has few treatment options, and the current therapeutic standard of care is dacarbazine which is a highly cytotoxic drug with severe side effects including vomiting, headache and hair loss. Treatmentwith dacarbazine has a median progression-free enhancement of survival time of only 1.5 months. Riluzole (RilutekTM) is a non-toxic drug and the ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Selective PLK2 Inhibitor for Cancer Therapy

    SBC: ONCONOVA THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The recent success of imatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia has made tyrosine and serine/threonine kinases as major targets for cancer therapy. Currently, since only a small fraction of the human kinome has been targeted by reasonably selective and potent inhibitors, there is an urgent need to develop stra ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Multifunctional Peptides for (MRI) Imaging

    SBC: CDG THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Our overall goal is to expand the role of CPPs in molecular imaging at the patient level using large animal models of human tumors and a peptide agent that inherently provides 1) preferential access to a wide variety ofhuman solid (and hematologic) tumor cells, 2) an increased intracellular concentration (2-12 fold) over histologically matched normal cells, and ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a plectin-1 targeted imaging agent for the detection of pancreatic can

    SBC: iTi Health            Topic: NCI

    DESCRIPTION (provided by applicant): Pancreatic ductal adenocarcinoma (PDAC) is an intractable clinical problem, typically presenting with metastasis at the time of diagnosis and exhibiting profound resistance to existing therapies. Currently, the standarddiagnostic course includes CT or MRI scans which do not have optimal sensitivity and specificity for accurately diagnosing and determining resec ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government